Knoa Pharma: all 73 studies

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mgCompletedNCT06719986Phase 1Results posted
• Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in ChildrenTerminatedNCT04987762Phase 4Results posted
• Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)TerminatedNCT04507204Phase 4Results posted
• Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health SystemCompletedNCT03299556Results posted
• A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the KneeCompletedNCT03028870Phase 2Results posted
• A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHDCompletedNCT02683265Phase 4Results posted
• Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHDCompletedNCT02470234Phase 4Results posted
• The Efficacy and Safety of PRC-063 in Adult ADHD PatientsCompletedNCT02139124Phase 3Results posted
• The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy VolunteersCompletedNCT01999114Phase 1Results posted
• Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back PainCompletedNCT01452529Phase 3Results posted
• Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.CompletedNCT01400139Phase 3Results posted
• Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001CompletedNCT01369615Phase 3Results posted
• Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back PainCompletedNCT01358526Phase 3Results posted
• Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in ChildrenCompletedNCT01324570Phase 3Results posted
• Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom SettingCompletedNCT01269463Phase 3Results posted
• Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and KetoconazoleCompletedNCT01259115Phase 1Results posted
• Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest PeriodsCompletedNCT01259102Phase 1Results posted
• Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHDCompletedNCT01239030Phase 3Results posted
• Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring OpioidsCompletedNCT01192295Phase 3Results posted
• Pharmacokinetics and Safety of ORF Tablets in Pediatric PatientsCompletedNCT01160614Phase 1Results posted
• Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension StudyCompletedNCT01151098Phase 3Results posted
• The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy VolunteersCompletedNCT01148537Phase 1Results posted
• Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension PhaseCompletedNCT01141283Phase 3Results posted
• Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension PhaseTerminatedNCT01135524Phase 3Results posted
• Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015TerminatedNCT01125917Phase 3Results posted
• To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different FacilitiesCompletedNCT01101321Phase 1Results posted
• A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different FacilitiesCompletedNCT01101308Phase 1Results posted
• A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) TabletsCompletedNCT01101191Phase 1Results posted
• To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) TabletsCompletedNCT01101178Phase 1Results posted
• To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) TabletsCompletedNCT01101165Phase 1Results posted
• A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) TabletsCompletedNCT01100320Phase 1Results posted
• A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) TabletsCompletedNCT01100086Phase 1Results posted
• A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) TabletsCompletedNCT01099709Phase 1Results posted
• Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of KneeCompletedNCT00531427Phase 3Results posted
• Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back PainCompletedNCT00490919Phase 3Results posted
• An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative PainCompletedNCT00465647Phase 4Results posted
• Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee ReplacementTerminatedNCT00403234Phase 2Results posted
• Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.TerminatedNCT00320801Phase 3Results posted
• Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.TerminatedNCT00315458Phase 3Results posted
• The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.CompletedNCT00315445Phase 3Results posted
• Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or KneeCompletedNCT00313846Phase 3Results posted
• Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back PainTerminatedNCT00313014Phase 3Results posted
• Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA PainCompletedNCT00312572Phase 3Results posted
• Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis PainTerminatedNCT00312221Phase 3Results posted
• Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant PainCompletedNCT00312195Phase 3Results posted
• Pharmacokinetic (PK) Evaluation of Nalmefene FormulationsCompletedNCT07543276Phase 1
• Study of Sunobinop on Craving in Alcohol Use DisorderCompletedNCT06545929Phase 2
• Study of Sunobinop on Alcohol Consumption in Alcohol Use DisorderCompletedNCT06545916Phase 2
• Clinical Outcomes From NalmefeneWithdrawnNCT05808881Phase 4
• A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the KneeTerminatedNCT02847702Phase 2
• Experimental Biomarker Study for Pain ThresholdsCompletedNCT02695745Phase 1
• A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHDStatus unknownNCT02677519Phase 4
• A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHDCompletedNCT02555150Phase 3
• Safety, Pharmacokinetics (PK), and Effectiveness of Hydrocodone Bitartrate (HYD) Extended-Release Tablets in ChildrenWithdrawnNCT02542098Phase 2
• The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult SubjectsCompletedNCT02243241Phase 1
• PRC-063 in an ADULT Workplace EnvironmentCompletedNCT02225639Phase 3
• Long-Term Safety of PRC-063 in Adolescents and Adults With ADHDCompletedNCT02168127Phase 3
• PRC-063 in Adolescent ADHDCompletedNCT02139111Phase 3
• Safety and Efficacy of PG101 for Dry Eye SyndromeCompletedNCT02078661Phase 1/2
• An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar ExtractionTerminatedNCT01900795Phase 2
• Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)CompletedNCT01688947Phase 2
• Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the KneeCompletedNCT01688934Phase 2
• A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back PainCompletedNCT01427283Phase 3
• Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back PainCompletedNCT01427270Phase 3
• Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe PainWithdrawnNCT01324544Phase 3
• Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent PainTerminatedNCT00365898Phase 3
• The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain.CompletedNCT00315887Phase 3
• The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.CompletedNCT00315874Phase 3
• The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.CompletedNCT00315848Phase 3
• Safety of the Buprenorphine Transdermal Delivery System in Subjects With Mod-to-Sev Pain Following Orthopedic Surgery.CompletedNCT00315835Phase 2
• Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.CompletedNCT00314652Phase 3
• Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.CompletedNCT00313833Phase 3
• Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) InfectionCompletedNCT00002078Phase 1

← Knoa Pharma overview and focus areas